Emergent BioSolutions (Emergent BioSolutions) Interest Expense

: $-88 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Emergent BioSolutions's interest expense for the three months ended in Dec. 2023 was $ -22 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-88 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Emergent BioSolutions's Operating Income for the three months ended in Dec. 2023 was $ -44 Mil. Emergent BioSolutions's Interest Expense for the three months ended in Dec. 2023 was $ -22 Mil. Emergent BioSolutions did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emergent BioSolutions Interest Expense Historical Data

The historical data trend for Emergent BioSolutions's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-38.40

-31.30

-34.50

-37.30

-87.90

Emergent BioSolutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-12.80	-17.90	-28.60	-19.70	-21.70

Emergent BioSolutions Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88 Mil.

Emergent BioSolutions (NYSE:EBS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emergent BioSolutions's Interest Expense for the three months ended in Dec. 2023 was $-22 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-44 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $447 Mil.

Emergent BioSolutions's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Emergent BioSolutions did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Emergent BioSolutions (Emergent BioSolutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ER4:Germany ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer	officer: Interim, EVP, BioSciences	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850